Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.40 |
| ▸ | NPC1 | O15118 | 3/20 | 0.40 |
| ▸ | RAB9A | P51151 | 3/20 | 0.40 |
| ▸ | TP53 | P04637 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.39 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | KLK7 | P49862 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | GLS | O94925 | 1/20 | 0.36 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.36 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19558427 | 0.86 | SMN1; SMN2 (0.39) | SMN1; SMN2NPC1RAB9ATP53LMNA | |
| SCHEMBL15981189 | 0.82 | GLS (0.39) | SMN1; SMN2NPC1RAB9ATP53LMNA | |
| SCHEMBL10812724 | 0.82 | L3MBTL1 (0.46) | NPC1RAB9ALMNAMAPTL3MBTL1 | |
| SCHEMBL3970824 | 0.81 | HTT (0.53) | SMN1; SMN2TP53L3MBTL1KDM4EKMT2A | |
| SCHEMBL1401007 | 0.81 | HTT (0.43) | SMN1; SMN2NPC1RAB9ALMNAKDM4E | |
| SCHEMBL2322779 | 0.81 | ALDH1A1 (0.47) | NPC1RAB9AMAPTL3MBTL1KDM4E | |
| SCHEMBL758293 | 0.80 | TSHR (0.47) | SMN1; SMN2RAB9ALMNAMAPTL3MBTL1 | |
| SCHEMBL2848804 | 0.79 | CYP17A1 (0.49) | SMN1; SMN2NPC1RAB9ATP53LMNA | |
| SCHEMBL11814078 | 0.78 | GAA (0.51) | SMN1; SMN2NPC1RAB9ALMNAMAPT | |
| SCHEMBL2286242 | 0.78 | CYP4F2 (0.61) | SMN1; SMN2NPC1RAB9ATP53LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11708371-B2 | Process for making beta 3 agonists and intermediates | MERCK SHARP & DOHME CORP. (US) | 2023-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11708371-B2 | Process for making beta 3 agonists and intermediates | ADRB3, ADRB2, ADRB1 | SMN1; SMN2 2205/4885NPC1 4251/4885RAB9A 2300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.